with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Total revenues for the company the last quarter was $134 million, a 7% decrease from last year. Register now to see our 7 Best Stocks for the Next 30 Days report - free today! Ionis Pharmaceuticals ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue ...

Hyderabad-based Dr Reddy's Laboratories (DRL) posted a 9.5 per cent year-on-year (Y-o-Y) decline in its consolidated profit ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

According to the WHO, about 40 percent of pharmaceutical products are based on natural sources, and 70 percent of people ...

The Portfolio Committee on Justice and Constitutional Development has expressed concern over allegations of a "toxic" environment in the office of the South African Human Rights Commission (SAHRC).

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...